Drug Discovery · Allschwil, Switzerland · Founded 2017 · Privately Held (backing)
Developer of cytokine therapeutics designed for the treatment of cancer and autoimmune diseases. Bright Peak Therapeutics is based in Allschwil, Switzerland and was founded in 2017. It has raised $244 million across 2 recorded rounds; the latest was a $90 million Series C in Jun 2024.
PMV mark · valuation
—
Oct 2026
Priced at
—
Total raised
$244.0M
Last round
Later Stage VC (Series C)
Jun 2024
No prints on record
No secondary trades in Bright Peak Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Bright Peak Therapeutics stock.
